Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A 10-Year Follow-up Study of the Natural History of Perianal Crohn's Disease in a Danish Population-Based Inception Cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Inflammatory Bowel Disease and Parkinson's Disease: A Reply to Letter to the Editor of Shih-Wei Lai

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  4. Inflammatory Bowel Disease and Parkinson's Disease: A Nationwide Swedish Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Social ties influence teamwork when managing clinical emergencies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Methotrexate for inflammatory bowel disease: time for reconsideration

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Biosimilars for Management of Crohn Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Primary infliximab treatment failure is common in patients with inflammatory bowel disease and represents a challenge to clinicians. Treatment options are limited. This study assessed the prognosis, defined as surgery-free survival, in patients with primary infliximab treatment failure as compared to patients without primary failure (initial responders). Furthermore, this study assessed the specter of medical therapies used after primary infliximab treatment failure along with treatment outcomes.

METHODS: Retrospective, observational, cohort study of patients with inflammatory bowel disease treated with infliximab as first-line anti-tumor necrosis factor treatment at a tertiary center. Primary infliximab treatment failure was defined as no clinical improvement during infliximab induction therapy resulting in discontinuation of infliximab therapy.

RESULTS: A total of 560 patients (Crohn's disease n = 353 and ulcerative colitis n = 207) were treated with infliximab. Among these, 81 (15%) had primary infliximab treatment failure after a median of 3 infusions (weeks 0, 2, and 6) (interquartile range 2-4). The median surgery-free survival was 196 days from first infusion. One year after primary infliximab treatment failure, the majority of patients (n = 51, 63%) had inflammatory bowel disease-related surgery (Crohn's disease n = 19, 58%; ulcerative colitis n = 32, 67%; P = 0.49). There was a markedly increased risk of surgery in patients with primary infliximab treatment failure as compared to initial responders: odds ratio 6.3 (3.8-10.6), P < 0.0001. Among 30 patients handled by medical therapies, 16 (53%) still had active disease 1 year after primary infliximab treatment failure.

CONCLUSIONS: Primary infliximab treatment failure is associated with poor outcome including high risk of surgery or sustained active disease despite medical interventions.

OriginalsprogEngelsk
TidsskriftInflammatory Bowel Diseases
Vol/bind23
Udgave nummer7
Sider (fra-til)1210-1217
Antal sider8
ISSN1078-0998
DOI
StatusUdgivet - jul. 2017

ID: 52417168